AKT1 and acute myeloid leukemia: Collectively, based on our results, we suggest that the sequence of administration of the drugs significantly impacted the anticancer outcome, and that the sequential treatment, including ATRA and PI3K/AKT inhibitor, exerts an optimal effect in AML, which needs further animal and clinical data.